Document/ExhibitDescriptionPagesSize
1: 10-Q Quarterly Report HTML 977K
2: EX-10.1 Material Contract HTML 72K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
13: R1 Cover Page HTML 74K
14: R2 Condensed Consolidated Statements of Income HTML 101K
(Unaudited)
15: R3 Condensed Consolidated Statements of Comprehensive HTML 52K
Income (Unaudited)
16: R4 Condensed Consolidated Statements of Comprehensive HTML 28K
Income (Unaudited) (Parenthetical)
17: R5 Condensed Consolidated Balance Sheets (Unaudited) HTML 157K
18: R6 Condensed Consolidated Balance Sheets (Unaudited) HTML 39K
(Parenthetical)
19: R7 Condensed Consolidated Statements of Cash Flows HTML 90K
(Unaudited)
20: R8 Basis of Presentation and Summary of Significant HTML 26K
Accounting Policies
21: R9 New Accounting Standards HTML 34K
22: R10 Revenue HTML 63K
23: R11 Net Income Per Share HTML 37K
24: R12 Inventories HTML 30K
25: R13 Leases HTML 59K
26: R14 Affiliated Companies HTML 27K
27: R15 Debt HTML 42K
28: R16 Derivative Financial Instruments HTML 134K
29: R17 Fair Value Measurements HTML 90K
30: R18 Accumulated Other Comprehensive Loss HTML 82K
31: R19 Shareholders' Equity HTML 170K
32: R20 Stock-Based Compensation HTML 27K
33: R21 Benefit Plans HTML 112K
34: R22 Other Expense (Income) HTML 60K
35: R23 Income Taxes HTML 26K
36: R24 Commitments and Contingencies HTML 26K
37: R25 Segment Information HTML 75K
38: R26 Basis of Presentation and Summary of Significant HTML 29K
Accounting Policies (Policies)
39: R27 Revenue (Tables) HTML 60K
40: R28 Net Income Per Share (Tables) HTML 35K
41: R29 Inventories (Tables) HTML 31K
42: R30 Leases (Tables) HTML 60K
43: R31 Debt (Tables) HTML 35K
44: R32 Derivative Financial Instruments (Tables) HTML 133K
45: R33 Fair Value Measurements (Tables) HTML 83K
46: R34 Accumulated Other Comprehensive Loss (Tables) HTML 83K
47: R35 Shareholders' Equity (Tables) HTML 166K
48: R36 Benefit Plans (Tables) HTML 105K
49: R37 Other Expense (Income) (Tables) HTML 57K
50: R38 Segment Information (Tables) HTML 70K
51: R39 Revenue - Revenue Recognition (Details) HTML 58K
52: R40 Revenue - Contracts and Liabilities (Details) HTML 33K
53: R41 Revenue - Contracts and Liabilities, Narrative HTML 40K
(Details)
54: R42 Net Income Per Share (Details) HTML 56K
55: R43 Inventories (Details) HTML 31K
56: R44 Leases - Lease Cost (Details) HTML 31K
57: R45 Leases - Lease Cash Flow and Supplemental HTML 27K
Information (Details)
58: R46 Leases - Lease Weighted Average (Details) HTML 26K
59: R47 Leases - Maturities of Operating Lease Liabilities HTML 45K
(Details)
60: R48 Affiliated Companies (Details) HTML 37K
61: R49 Debt - Long-term Debt (Details) HTML 47K
62: R50 Debt - Credit Agreement (Details) HTML 44K
63: R51 Derivative Financial Instruments - Foreign HTML 63K
Exchange Rate Risk (Details)
64: R52 Derivative Financial Instruments - Effects of HTML 86K
Derivative Instruments on OCI and Earnings
(Details)
65: R53 Fair Value Measurements - Assets and Liabilities HTML 69K
Recorded at Fair Value (Details)
66: R54 Fair Value Measurement - Level 3 Fair Value HTML 50K
Measurements (Details)
67: R55 Fair Value Measurement - Other Financial HTML 26K
Instruments (Details)
68: R56 Accumulated Other Comprehensive Loss - Components HTML 61K
of Accumulated Other Comprehensive Income
(Details)
69: R57 Accumulated Other Comprehensive Loss - Other HTML 88K
Comprehensive Loss Reclassifications (Details)
70: R58 Shareholder's Equity - Change in Shareholders' HTML 113K
Equity (Details)
71: R59 Shareholder's Equity - Supplemental Equity HTML 24K
Information (Details)
72: R60 Stock-Based Compensation (Details) HTML 59K
73: R61 Benefit Plans - Schedule of Components of Net HTML 64K
Periodic Benefit Cost (Details)
74: R62 Benefit Plans - Narrative (Details) HTML 27K
75: R63 Other Expense (Income) - Other Expense (Income) HTML 37K
(Details)
76: R64 Other Expense (Income) - Restructuring and Related HTML 67K
Charges (Details)
77: R65 Other Expense (Income) - Other Items (Details) HTML 35K
78: R66 Income Taxes (Details) HTML 30K
79: R67 Segment Information (Details) HTML 66K
81: XML IDEA XML File -- Filing Summary XML 146K
12: XML XBRL Instance -- wst-20210930_htm XML 3.11M
80: EXCEL IDEA Workbook of Financial Reports XLSX 94K
8: EX-101.CAL XBRL Calculations -- wst-20210930_cal XML 202K
9: EX-101.DEF XBRL Definitions -- wst-20210930_def XML 455K
10: EX-101.LAB XBRL Labels -- wst-20210930_lab XML 1.45M
11: EX-101.PRE XBRL Presentations -- wst-20210930_pre XML 828K
7: EX-101.SCH XBRL Schema -- wst-20210930 XSD 133K
82: JSON XBRL Instance as JSON Data -- MetaLinks 422± 580K
83: ZIP XBRL Zipped Folder -- 0000105770-21-000083-xbrl Zip 289K
In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the “Company”) for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on
the date hereof (the “Report”), I, Bernard J. Birkett, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
